References
- Yoshizawa K, Morikawa Y, Abemastu T, Kimoto T, Hamada K, Fukuda K, Koyama M, Miura T, Yamada T, Masuda R, et al. A comparison of the amounts of unused fentanyl transdermal patches to select. Jpn Hosp. 2009;45:773–6.
- Miyazaki T, Hanaoka K, Ogawa S, Suzuki Y, Nogami M, Taguma S. Clinical trial II of Durotep® MT patch in patients with chronic non-cancer pain. J New Rem Clin. 2010;59:188–200.
- Freynhagen R, von Giesen HJ, Busche P, Sabatowski R, Konrad C, Grond S. Switching from reservoir to matrix systems for the transdermal delivery of fentanyl: a prospective, multicenter pilot study in outpatients with chronic pain. J Pain Symptom Manage. 2005;30(3):289–97. doi:10.1016/j.jpainsymman.2005.03.015.
- Yamamoto K, Kojima M, Iguchi H, Ohta T. Measurement of amount of fentanyl remaining in used patches: investigation of clinical factors affecting the remaining amounts in 4 patients. Yakugaku Zasshi. 2008;128(6):959–64. doi:10.1248/yakushi.128.959.
- Jeffery SM, Pepe JJ, Popovich LM, Vitagliano G. Gabapentin for hot flushes in prostate cancer. Ann Pharmacother. 2002;36(3):433–6. doi:10.1345/aph.1A139.
- Suzuki K, Kobayashi M, Tokue A. Clinical evaluation of hot flushes developing during endocrine therapy for prostate carcinoma. Nihon Hinyokika Gakkai Zasshi. 2003;94(6):614–20. doi:10.5980/jpnjurol1989.94.614.
- Kouriefs C, Georgiou M, Ravi R. Hot flushes and and prostate cancer: parhogenesis and treatment. BJU Int. 2002;89(4):379–83. doi:10.1046/j.1464-4096.2001.01761.x.
- Berendsen HH. The role of serotonin in hot flushes. Maturitas. 2000;36(3):155–64. doi:10.1016/S0378-5122(00)00151-1.
- Spetz AC, Pettersson B, Varenhorst E, Theodorsson E, Thorell LH, Hammar M. Momentary increase in plasma calcitonin gene-related peptide is involved in hot flasheses in men treated with castration for carcinoma of the prostate. J Urol. 2001;166(5):1720–3.
- Hedlund PO. Side effects of endocrine treatment and their mechanisms: castration, antiandrogens, and estrogens. Prostate. 2000;45(S10):32–7. doi:10.1002/1097-0045(2000)45:10+ <32::aid-pros7 > 3.0.co;2-v.
- Sakai H, Igawa T, Tsurusaki T, Yura M, Kusaba Y, Hayashi M, Iwasaki S, Hakariya H, Hara T, Kanetake H. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer. Urology. 2009;73(3):635–40. doi:10.1016/j.urology.2008.09.013.
- Stearns V, Ullmer L, López JF, Smith Y, Isaacs C, Hayes D. Hot flushes. Lancet. 2002;360(9348):1851–61. doi:10.1016/S0140-6736(02)11774-0.
- Suneel KG, Mary S, Robert G, Stephen SH. System functionality and physicochemical model of fentanyl transdermal system. J Pain Symptom Manage. 1992;7:S17–S26. doi:10.1016/0885-3924(92)90049-n.
- Heiskanen T, Mätzke S, Haakana S, Gergov M, Vuori E, Kalso E. Transdermal fentanyl in cachectic cancer patients. Pain. 2009;144(1–2):218–22. doi:10.1016/j.pain.2009.04.012.